Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
Items 501–600 of 1,000
Zheng, M., Zhang, H., Dai, M., Yu, H., Hu, Y., Cheng, L., Wang, H., Chen, Q., Tan, M., Guo, Y., et al. (2025) · Nano Letters · doi:10.1021/acs.nanolett.4c05625 · Cited by 26
Targeting angiogenesis: Lessons from 25 years of normalizing tumor vasculature
Subudhi, S., Lee, S., & Jain, R. K. (2026) · Cell · doi:10.1016/j.cell.2026.03.016 · Cited by 31
Self-citationHolbrook, M. C., Goad, D. W., & Grdzelishvili, V. Z. (2021) · Cancers · doi:10.3390/cancers13051171 · Cited by 26
Emerging technologies provide insights on cancer extracellular matrix biology and therapeutics
Cruz‐Acuña, R., Vunjak‐Novakovic, G., Burdick, J. A., & Rustgi, A. K. (2021) · iScience · doi:10.1016/j.isci.2021.102475 · Cited by 26
Balkrishnan, R., Desai, R. P., Narayan, A. P., Camacho, F., Flausino, L. E., & Chammas, R. J. (2021) · Cancer Medicine · doi:10.1002/cam4.4088 · Cited by 26
Nuzzo, P. V., Adib, E., Weise, N., Curran, C. R., Stewart, T. F., Freeman, D. A., Nassar, A. H., Alaiwi, S. A., Bakouny, Z., McGregor, B. A., et al. (2022) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2022.04.012 · Cited by 26
Self-citationPhysics of the tumor vasculature: Theory and experiment
Rieger, H., Fredrich, T., & Welter, M. (2016) · The European Physical Journal Plus · doi:10.1140/epjp/i2016-16031-9 · Cited by 28
Nanoparticles for Targeting Intratumoral Hypoxia: Exploiting a Potential Weakness of Glioblastoma
Aldea, M. D., Florian, I. A., Kacsó, G., Craciun, L., Boca, S., Şoriţău, O., & Florian, I. Ş. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1947-8 · Cited by 27
Wadsworth, B. J., Cederberg, R. A., Lee, C.-M., Firmino, N. S., Franks, S. E., Pan, J., Colpo, N., Lin, K., Bénard, F., & Bennewith, K. L. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.015 · Cited by 27
The Role of the Renin–Angiotensin System in the Cancer Stem Cell Niche
Kilmister, E. J., & Tan, S. T. (2021) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554211026295 · Cited by 26
Liu, L., Wan, W., Chang, Y., Ao, L., Xu, Y., & Xu, X. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03527-z · Cited by 36
“…and HA by CAFs through inhibiting TGF-β1-mediated pro-fibrotic signaling, thereby improving tumor vascular perfusion and drug delivery efficiency [231], enhancing the effects of chemotherapy, radiotherapy, and immunotherapy [189, 232–234], and significantly inhibiting breast cancer progression…”
Targeting metastasis with nanomedicine
Pallares, R. M., Consolino, L., Wang, A., Lorenzi, F. D., Kiessling, F. M., Schroeder, A., & Lammers, T. (2025) · Nature Reviews Bioengineering · doi:10.1038/s44222-025-00358-7 · Cited by 29
“T cells 66–69 .”
Luo, W., Yang, G., Qiu, J., Luan, J., Zhang, Y., You, L., Feng, M., Zhao, F., Liu, Y., Cao, Z., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2384 · Cited by 25
Sabatasso, S., Fernández-Palomo, C., Hlushchuk, R., Fazzari, J., Tschanz, S. A., Pellicioli, P., Krisch, M. H., Laissue, J. A., & Djonov, V. (2021) · Cancers · doi:10.3390/cancers13092103 · Cited by 27
Sulheim, E., Hanson, I., Snipstad, S., Vikedal, K., Mørch, Y. A., Boucher, Y., & Davies, C. D. L. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100147 · Cited by 27
Self-citationWang, C., Cheng, T., Lu, Q., Li, W., Liu, B., Yue, L., Du, M., Sheng, W., Lu, Z., Yang, J., et al. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106624 · Cited by 26
Sousa-Junior, A. A., Mello-Andrade, F., Rocha, J. V. R., Hayasaki, T. G., de Curcio, J. S., Silva, L. D. C., de Santana, R. C., Lima, E. M., Cardoso, C. G., Silveira-Lacerda, E. D. P., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030943 · Cited by 25
“Jain’s research group previously showed that losartan reduces collagen and hyaluronan production, affecting the tumor extracellular matrix, thus resulting in increased nanoparticle delivery [33].”
BackgroundAnalyzing spatiotemporal distribution of uniquely fluorescent nanoparticles in xenograft tumors
Stirland, D. L., Matsumoto, Y., Toh, K., Kataoka, K., & Bae, Y. H. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.02.016 · Cited by 26
Anti-lymphangiogenesis for boosting drug accumulation in tumors
Wang, C., Xu, J., Cheng, X., Sun, G., Li, F., Nie, G., & Zhang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01794-4 · Cited by 27
Jimenez-Macias, J. L., Vaughn-Beaucaire, P. C., Bharati, A., Xu, Z., Forrest, M. E., Hong, J. S., Sun, M., Schmidt, A., Clark, J., Hawkins, W. M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adr1481 · Cited by 27
“In this regard, normalized blood flow can also promote drug accumulation in solid tumors ( 77, 78 ).”
Zhang, C., Gau, E., Sun, W., Zhu, J., Schmidt, B., Pich, A., & Shi, X. (2019) · Biomaterials Science · doi:10.1039/c9bm01132c · Cited by 24
Khoshghamat, N., Jafari, N., Tolou, V., Azami, S., Mirnourbakhsh, S. H., Khazaei, M., Ferns, G. A., Rajabian, M., & Avan, A. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119118 · Cited by 24
Effects of biomechanical forces on the biological behavior of cancer stem cells
Tian, B. R., Lin, W., & Zhang, Y. (2021) · Journal of Cancer · doi:10.7150/jca.60893 · Cited by 25
“For example, losartan, an antagonist of angiotensin II receptor 1, degrades both collagen I and HA by blocking TGF-β signal [83].”
BackgroundMesenchymal stem cells and cancer‐associated fibroblasts as a therapeutic strategy for breast cancer
Borzone, F. R., Giorello, M. B., Sanmartin, M. C., Yannarelli, G., Martinez, L. M., & Chasseing, N. A. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15861 · Cited by 26
Kuznetsova, A. V., Попова, О. П., Panchenkov, D. N., Dyuzheva, Т. G., & Aa, I. (2022) · Clinical and Experimental Medicine · doi:10.1007/s10238-022-00886-1 · Cited by 24
“In addition to the above, a number of studies have shown that the use of angiotensin system inhibitors, such as losartan, an angiotensin II type 1 receptor blocker, and lisinopril, an angiotensin converting enzyme inhibitor, reduce peritumoral stroma by reducing collagen and HA levels, increase perfusion and enhance t…”
BackgroundTranslational nanomedicine potentiates immunotherapy in sarcoma by normalizing the microenvironment
Mpekris, F., Panagi, M., Michael, C., Voutouri, C., Tsuchiya, M., Wagatsuma, C., Kinoh, H., Osada, A., Akinaga, S., Yoshida, S., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.12.016 · Cited by 24
Self-citationMollah, F., & Varamini, P. (2021) · Biomedicines · doi:10.3390/biomedicines9121921 · Cited by 26
Multiphoton fluorescence lifetime imaging of chemotherapy distribution in solid tumors
Carlson, M., Watson, A. L., Anderson, L. K., Largaespada, D. A., & Provenzano, P. P. (2017) · Journal of Biomedical Optics · doi:10.1117/1.jbo.22.11.116010 · Cited by 28
“However, we note that the inner regions of the PNSTs are either not perfused or not well perfused with doxorubicin, consistent with our understanding of poor molecular transport phenomena in solid tumors.(20,23,25,27) Furthermore, most well perfused regions reflect a spectrum of doxorubicin compartmentalization behavi…”
The emerging promise of tumour mechanobiology in cancer treatment
Papavassiliou, K. A., Basdra, E. K., & Papavassiliou, A. G. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.112938 · Cited by 25
CAFs vs. TECs: when blood feuds fuel cancer progression, dissemination and therapeutic resistance
Coursier, D., & Calvo, F. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00931-z · Cited by 25
“…et al. showed that administration of the angiotensin inhibitor losartan in pre-clinical models reduced CAF density and activation, leading to a significant decrease in collagen and hyaluronan produc - tion [137], which are directly associated with aberrant vasculature and poor perfusion [133, 134].”
BackgroundSun, Y., Yin, Z., Li, S., Wu, L., Zhang, Y., Zhao, Y., SANTOS, I. L. G. D., Subudhi, S., Lei, P., Muzikansky, A., et al. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02863-9 · Cited by 25
“In our attempts to normalize the TME, we discovered that angiotensin II receptor 1 (AT1) is a key regulator of the compressive solid stress [21, 22].”
Self-citationReprogramming the tumor microenvironment to overcome immunotherapy resistance in pancreatic cancer
Hui, X., Tian, X., Ding, S., Sun, A., Zhao, T., & Wang, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1717062 · Cited by 30
Chen, J., Zhang, Z., Li, Y., Zeng, H., Li, Z., Wang, C., Chen, X., Deng, Q., Wang, Q., Yang, X., et al. (2022) · Journal of Materials Chemistry B · doi:10.1039/d2tb01812h · Cited by 24
The Matrix Reloaded—The Role of the Extracellular Matrix in Cancer
Raskov, H., Gaggar, S., Tajik, A., Orhan, A., & Gögenür, I. (2023) · Cancers · doi:10.3390/cancers15072057 · Cited by 25
An, Y., Pu, N., Jia, J.-B., Wang, W., & Liu, L. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188958 · Cited by 26
Zhou, X., Zhang, P., Liu, N., Zhang, X., Lv, H., Xu, W., & Huo, M. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.061 · Cited by 23
Datta, M., Via, L. E., Dartois, V. A., Weiner, D. M., Zimmerman, M., Kaya, F., Walker, A. M., Fleegle, J. D., Raplee, I., McNinch, C., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2321336121 · Cited by 26
“Losartan, an AT1 receptor antagonist, reduces matrix by blocking profibrotic pathways and cytokines such as TGF - β 1 (16, 21), which has been implicated as a driver of fibrosis in TB granulomas as it is secreted by fibroblasts, regulatory T cells, and macrophages (34).”
BackgroundResultInfluentialSelf-citationGene and cell therapy for pancreatic cancer
Singh, H. M., Ungerechts, G., & Tsimberidou, A. M. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1001734 · Cited by 24
“Angiotensin antagonism was subsequently shown to induce the remodeling of extracellular matrix (ECM) components and increase the vascular perfusion of pancreatic tumors in an orthotopic model [76].”
BackgroundControlled nanoparticle release from a hydrogel by DNA-mediated particle disaggregation
Nowald, C., Käsdorf, B. T., & Lieleg, O. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.12.015 · Cited by 23
Cerullo, M., Gani, F., Chen, S. Y., Canner, J. K., & Pawlik, T. M. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4021-8 · Cited by 23
Nataf, S., Guillen, M., & Pays, L. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20235934 · Cited by 24
Zhang, P., Zhang, Y. X., Ding, X., Xiao, C., & Chen, X. (2020) · Biomaterials Science · doi:10.1039/d0bm00466a · Cited by 23
Research progress in tumor targeted immunotherapy
Fang, Y., Yu, A., Ye, L., & Zhai, G. (2021) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2021.1882992 · Cited by 23
“produced by TAFs in breast and pancreatic cancer, increasing drug and oxygen delivery, and improving chemotherapy results [108].”
BackgroundBhattarai, S., Mackeyev, Y., Venkatesulu, B. P., Krishnan, S., & Singh, P. K. (2021) · Nanoscale · doi:10.1039/d1nr05385j · Cited by 22
Measurement of Tumor Pressure and Strategies of Imaging Tumor Pressure for Radioimmunotherapy
Kim, H., Yu, A., Lee, J., Lee, Y., Lim, S. M., & Kim, J. S. (2019) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-019-00598-7 · Cited by 24
The role of the renin-angiotensin system inhibitors in malignancy: a review.
Yang, J., Yang, X., Gao, L., Zhang, J., Cheng, Y., & Huang, Y. (2021) · American Journal of Cancer Research · Cited by 33
Cannon, A. C., Thompson, C. M., Bhatia, R., Armstrong, K. A., Solheim, J. C., Kumar, S., & Batra, S. K. (2021) · Journal of Gastroenterology · doi:10.1007/s00535-021-01800-4 · Cited by 23
Leveraging cellular mechano-responsiveness for cancer therapy
Hyun, J., & Kim, H. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2021.11.006 · Cited by 23
Stromal Homeostasis-Restoring Nanomedicine Enhances Pancreatic Cancer Chemotherapy
Yu, N., Zhang, X., Zhong, H., Mu, J., Li, X., Liu, T., Shi, X., Liang, X., & Guo, S. (2022) · Nano Letters · doi:10.1021/acs.nanolett.2c03663 · Cited by 22
Benjakul, N., Prakobphol, N., Tangshewinsirikul, C., Dulyaphat, W., Svasti, J., Charngkaew, K., & Kangsamaksin, T. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279001 · Cited by 26
Stehle, D., Barresi, M., Schulz, J., & Feil, R. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108337 · Cited by 22
Modulating tumor mechanics with nanomedicine for cancer therapy
Zhao, Q., Chen, J., Zhang, Z., Xiao, C., Zeng, H., Chen, X., Yang, X., & Li, Z. (2023) · Biomaterials Science · doi:10.1039/d3bm00363a · Cited by 23
Nanoparticles for tumor targeting
Jiang, T., Jin, K., Liu, X., & Pang, Z. (2017) · Elsevier eBooks · doi:10.1016/b978-0-08-101914-6.00008-9 · Cited by 30
Vallejo-Ardila, D. L., Fifis, T., Burrell, L. M., Walsh, K. A., & Christophi, C. (2018) · Oncotarget · doi:10.18632/oncotarget.26174 · Cited by 23
“A collateral effect of decreasing tumor desmoplasia is the decompression of tumor blood vessels and subsequent reduction of tumor hypoxia by increasing perfusion, which may also enhance antitumor immunity [96].”
BackgroundUrsu, R., Thomas, L., Psimaras, D., Chinot, O. L., Rhun, É. L., Ricard, D., Charissoux, M., Cuzzubbo, S., Sejalon, F., Quillien, V., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.025 · Cited by 23
Zhou, C., Song, X., Guo, C., Tan, Y., Zhao, J., Yang, Q., Chen, D., Tan, T., Sun, X., Gong, T., et al. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b11307 · Cited by 23
Zhou, Z., Yang, Y., Zhang, Q., & Cheng, Y. (2020) · Biomaterials Science · doi:10.1039/c9bm01843c · Cited by 23
Hamy, A., Derosa, L., Valdelièvre, C., Yonekura, S., Opolon, P., Priour, M., Guerin, J., Pierga, J., Asselain, B. J. R., Croze, D. D., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1677427 · Cited by 22
Transforming cancer cells for long-term living with cancer: An inspiring new approach
Jiang, M., Gu, D.-N., Liu, F.-R., Lin, C.-J., & Tian, L. (2023) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2023.02.03 · Cited by 22
Kawakubo, M., Demehri, S., & Manstein, D. (2017) · PLoS ONE · doi:10.1371/journal.pone.0184852 · Cited by 21
“Both requirements can be a challenge within tumors, which are often characterized by blood vessel compression and hypoxemia due to the tumor growth [21, 22].”
Kocher, F., Tymoszuk, P., Amann, A., Sprung, S., Salcher, S., Daum, S., Haybaeck, J., Rinnerthaler, G., Huemer, F., Kauffmann-Guerrero, D. E., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.06.020 · Cited by 21
Magnetic resonance elastography of malignant tumors
Pagé, G., Garteiser, P., & BEERS, B. E. V. (2022) · Frontiers in Physics · doi:10.3389/fphy.2022.910036 · Cited by 23
“In preclinical models of pancreatic adenocarcinoma, losartan was used to decrease solid stress and decompress blood vessel, improving chemotherapy efficacy [96].”
MethodThe role of tumor immune microenvironment in chordoma: promising immunotherapy strategies
Xu, J., Shi, Q., Wang, B., Ji, T., Guo, W., Ren, T., & Tang, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1257254 · Cited by 21
Desmoplasia in cervical cancer is associated with a more aggressive tumor phenotype
Wolf, B., Weydandt, L., Dornhöfer, N., Hiller, G. G. R., Höhn, A. K., Nel, I., Jain, R. K., Horn, L., & Aktas, B. (2023) · Scientific Reports · doi:10.1038/s41598-023-46340-4 · Cited by 24
Self-citationModelling and breaking down the biophysical barriers to drug delivery in pancreatic cancer
Kpeglo, D., Haddrick, M., Knowles, M. A., Evans, S. D., & Peyman, S. A. (2024) · Lab on a Chip · doi:10.1039/d3lc00660c · Cited by 22
Remodeling of extracellular matrix due to solid stress accumulation during tumor growth
Pirentis, A. P., Polydorou, C., Papageorgis, P., Voutouri, C., Mpekris, F., & Stylianopoulos, T. (2015) · Connective Tissue Research · doi:10.3109/03008207.2015.1047929 · Cited by 23
Self-citationStress alleviation strategy in cancer treatment: Insights from a mathematical model
Mpekris, F., Voutouri, C., Papageorgis, P., & Stylianopoulos, T. (2018) · ZAMM ‐ Journal of Applied Mathematics and Mechanics / Zeitschrift für Angewandte Mathematik und Mechanik · doi:10.1002/zamm.201700270 · Cited by 24
Self-citationBarrett, A. S., Maller, O., Pickup, M. W., Weaver, V. M., & Hansen, K. C. (2018) · Journal of Immunology and Regenerative Medicine · doi:10.1016/j.regen.2018.03.002 · Cited by 22
Novel prognostic markers within the CD44‐stromal ligand network in pancreatic cancer
Franklin, O., Billing, O., Öhlund, D., Berglund, A., Herdenberg, C., Wang, W., Hellman, U., & Sund, M. (2018) · The Journal of Pathology Clinical Research · doi:10.1002/cjp2.122 · Cited by 23
“Depletion of stromal hyaluronan is a promising therapeutic strategy in preclinical studies [18,41].”
BackgroundChen, X., Jia, F., Huang, Y., Jin, Q., & Ji, J. (2022) · ACS Applied Bio Materials · doi:10.1021/acsabm.2c00486 · Cited by 22
Zhang, X., Yang, H., & Zhang, R. (2019) · Bioscience Reports · doi:10.1042/bsr20190230 · Cited by 21
Pantziarka, P., Bouche, G., Meheus, L., Sukhatme, V., & Sukhatme, V. P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.443 · Cited by 77
Gold nanoparticles and obese adipose tissue microenvironment in cancer treatment
Essa, N., O’Connell, F., Prina‐Mello, A., O'Sullivan, J. N., & Marcone, S. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.10.017 · Cited by 21
Targeting tumor microenvironment and metastasis in children with solid tumors
Wessel, K. M., & Kaplan, R. N. (2021) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000001082 · Cited by 21
Rasel, M. S. I., Mohona, F. A., Akter, W., Kabir, S., Chowdhury, A. A., Chowdhury, J. A., Hassan, M. A., Mamun, A. A., Ghose, D. K., Ahmad, Z., et al. (2022) · Journal of Oncology · doi:10.1155/2022/9396760 · Cited by 27
“[94] B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y. Boucher, and R. K. Jain, “Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 7, pp. 2909–2914, 011.”
BackgroundZhao, J., Zhu, Y., Li, Z., Liang, J., Zhang, Y., Zhou, S., Zhang, Y., Fan, Z., Shen, Y., Liu, Y., et al. (2022) · Biomaterials Science · doi:10.1039/d2bm00770c · Cited by 21
New Treatment Options in Metastatic Pancreatic Cancer
Fudalej, M. M., Kwaśniewska, D., Nurzyński, P., Badowska-Kozakiewicz, A. M., Mękal, D., Czerw, A. I., Sygit, K., & Deptała, A. (2023) · Cancers · doi:10.3390/cancers15082327 · Cited by 23
“(2013) proved that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, which results in increased vascular perfusion and drug delivery and potentiates chemotherapy in PC models [74].”
BackgroundSamuel, T., Rapic, S., O’Brien, C., Edson, M., Zhong, Y., & DaCosta, R. S. (2023) · Science Advances · doi:10.1126/sciadv.ade8672 · Cited by 24
Mechanical stress-induced autophagic response: A cancer-enabling characteristic?
Das, J., Chakraborty, S. K., & Maiti, T. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.05.017 · Cited by 20
Enjalbert, R., Hardman, D., Krüger, T., & Bernabéu, M. O. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025236118 · Cited by 23
“Second, previous studies have shown that decompressing tumor vessels leads to increased survival rates (8, 9).”
BackgroundInfluentialTowards Immunotherapy-Induced Normalization of the Tumor Microenvironment
Melo, V. A., Bremer, E., & Martin, J. D. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.908389 · Cited by 23
“, structural components of the tissue including collagen I and hyaluronan) that transmit forces towards compressing blood vessels (Stylianopoulos et al., 2012; Chauhan et al., 2013; Chauhan et al., 2014) (Figure 1B).”
BackgroundSelf-citationHigh-resolution 3D visualization of nanomedicine distribution in tumors
Moss, J. I., Barjat, H., Emmas, S.-A., Strittmatter, N., Maynard, J., Goodwin, R. J. A., Storm, G., Lammers, T., Puri, S., Ashford, M. B., et al. (2020) · Theranostics · doi:10.7150/thno.37178 · Cited by 19
“Nanomedicine accumulation, distribution and retention are critical determinants of therapeutic effect (in addition to sustaining peripheral pharmacokinetic exposure), and it is apparent that the tumor microenvironment affects treatment outcomes in preclinical models [26-31].”
BackgroundSmart on-demand drug release strategies for cancer combination therapy
Huang, X., Ji, M., Shang, X., Zhang, H., Zhang, X., Zhou, J., & Yin, T. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113782 · Cited by 19
The m7G Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling
Xie, J., Mo, T., Li, R., Zhang, H., Liang, G., Ma, T., Chen, J., Xie, H., Wen, X., Hu, T., et al. (2023) · Cancers · doi:10.3390/cancers15225454 · Cited by 19
“The extensive fibrosis within PDAC tissues, termed as desmoplasia, dramatically reduces the delivery and efficacy of chemotherapy by decreasing vessel perfusion [2].”
BackgroundHou, X., Shen, Y., Huang, B., Li, Q., Li, S., Jiang, T., Shan, X., Xu, W., Liu, S., Wu, S., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02871-0 · Cited by 22
“For in vivo bio-degradable and bio-compatible behaviour, fibrin gel was injected into the subcutaneous tissue of the abdominal cavity of BALB/c mice (200 µL per sample) and executed at 0, 1, 3, 7, 14, 21 and 28 day.”
BackgroundMethodQiao, J.-X., Guo, D., Tian, H., Wang, Z., Fan, Q.-Q., Tian, Y., Sun, J., Zhang, X., Zou, J., Cheng, J., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101358 · Cited by 29
Lai, Y., Chiang, C., Kao, T.-H., & Chen, S.-Y. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s161314 · Cited by 19
Naumenko, V., Vodopyanov, S., Vlasova, K. Y., Potashnikova, D. M., Melnikov, P., Vishnevskiy, D. A., Garanina, A. S., Valikhov, M. P., Lipatova, A. V., Chekhonin, V. P., et al. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.12.014 · Cited by 21
de Miranda, F. S., Guimarães, J. P. T., Menikdiwela, K. R., Mabry, B., Dhakal, R., Rahman, R. L., Moussa, H. M., & Moustaïd‐Moussa, N. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111245 · Cited by 24
Chen, X., Jin, R., Jiang, Q., Bi, Q., He, T., Song, X., Barz, M., Ai, H., Shuai, X., & Nie, Y. (2021) · Small · doi:10.1002/smll.202100609 · Cited by 26
Hou, L., Chen, D., Wang, R., Wang, R., Zhang, H., Zhang, Z., Nie, Z., & Lu, S. (2021) · Angewandte Chemie · doi:10.1002/ange.202014397 · Cited by 21
Exploring the Biology of Cancer-Associated Fibroblasts in Pancreatic Cancer
Bryce, A. S., Dreyer, S. B., Froeling, F. E. M., & Chang, D. K.-F. (2022) · Cancers · doi:10.3390/cancers14215302 · Cited by 20
Vincent, P., Wang, H., Nieskoski, M. D., Gunn, J. R., Marra, K., Hoopes, P. J., Samkoe, K. S., Doyley, M. M., Hasan, T. G., & Pogue, B. W. (2020) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2019.2963562 · Cited by 22
“damages tumor vasculature [8] and the lymphatic system [9].”
BackgroundThe role and mechanism of compressive stress in tumor
Tan, M., Song, B., Zhao, X., & Du, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1459313 · Cited by 23
“However, compression also reduces blood perfusion and affects drug delivery, which can interfere with tumor treatment (62, 63).”
BackgroundResponsive nanomedicine strategies achieve pancreatic cancer precise theranostics
Li, F., Tang, Z., Zheng, Y., Jiang, T., Deng, L., Dai, W., Zhao, Y., Zheng, N., Liu, S., Fan, Y., et al. (2025) · Bioactive Materials · doi:10.1016/j.bioactmat.2025.08.012 · Cited by 36
“In PDAC, responsive strategies are particularly advantageous: they can penetrate the dense stroma, respond to hypoxia and acidosis to activate therapeutic payloads precisely at the tumor site, and remodel the extracellular matrix to alleviate mechanical barriers [23,24].”
Cancer-associated fibroblasts as accomplices to confer therapeutic resistance in cancer
Wang, W., Cheng, B., & Yu, Q. (2022) · Cancer Drug Resistance · doi:10.20517/cdr.2022.67 · Cited by 19
Nicolini, G., Balzan, S., & Forini, F. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121575 · Cited by 19
Mu, H., Ta, Y. N., Tham, M. J. R., Hsu, F., Lin, Y., Huang, H., Sung, Y., Huang, C., Wu, C.-L., Chang, C., et al. (2023) · Advanced Functional Materials · doi:10.1002/adfm.202303033 · Cited by 19
Self-citationMpekris, F., Panagi, M., Charalambous, A., Voutouri, C., Michael, C., Papoui, A., & Stylianopoulos, T. (2024) · Neoplasia · doi:10.1016/j.neo.2024.100990 · Cited by 20
“However, mechanother-apeutics cannot decompress the majority of the vessels but only a percentage of them [26].”
BackgroundSelf-citationTawfic, A. A., Ibrahim, H. M., Mohammed-Geba, K., & El‐Magd, M. A. (2024) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-024-00535-4 · Cited by 18
“Inflammation may be triggered by cancer cells in two ways: by producing cytokines directly [64] or by physically damaging normal tissue [65].”
Background
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.